Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07118527) titled 'A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Condition:
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Intervention:
Drug: SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or F...